Arkema sale leads to indigestion
Groupe Bruxelles Lambert sold its entire 10.01% stake in French chemicals firm Arkema following a strong run in the stock price over the last six months and after the company reported results last week. It traded weakly following the tightly-priced deal, but bankers and analysts away from the deal remain bullish on the stock and expect the indigestion to clear soon.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts